BioSpace News Archive

Biotech Beach

Innovus Pharma Announces the Launch of its Hemorrhoid Drug Xyralid® in Canada

Xyralid®, a Lidocaine-based Cream for the Relief of Pain and Symptoms Caused by Hemorrhoids, is the Sixth Innovus Pharma Product launched in Canada to Date

April 26, 2018
·
4 min read
Pharm Country

Praxair Declares Dividend in Second Quarter 2018

The board of directors of Praxair, Inc. (NYSE: PX) has declared a quarterly dividend of 82.50 cents per share, unchanged from the previous quarter.

April 26, 2018
·
1 min read
Business

Novocure Reports First Quarter 2018 Financial Results and Provides Company Update

2,009 active patients at March 31, 2018, an increase of 59 percent versus March 31, 2017

April 26, 2018
·
13 min read
Business

Universal Health Realty Income Trust Reports 2018 First Quarter Financial Results

Consolidated Results of Operations - Three-Month Periods Ended March 31, 2018 and 2017:

April 26, 2018
·
27 min read
Business

Magellan Health Reports First Quarter 2018 Financial Results

Magellan Health, Inc. (NASDAQ: MGLN) today announced financial results for the first quarter ended March 31, 2018

April 26, 2018
·
20 min read
Pharm Country

BD Launches BD FACSymphony™ S6 High Parameter Cell Sorter to Enable Sorting of Rare Cell Types

New Cell Sorter Extends BD’s Robust Portfolio of Flow Cytometry Research Solutions

April 26, 2018
·
3 min read
Antibe Therapeutics Announces CEO Letter to Shareholders

Letter to stakeholders from Antibe CEO.

April 26, 2018
·
8 min read
FDA

Foundation Medicine’s New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug Administration

The new assay will include more than 70 genes and genomic biomarkers for microsatellite instability (MSI) and blood tumor mutational burden (bTMB).

April 26, 2018
·
5 min read
TSO3 Details Results of Prion Inactivation Studies

Studies demonstrate the efficacy of the STERIZONE® VP4 Sterilizer for inactivation of prions.

April 26, 2018
·
4 min read
Business

Fujirebio Enters into Agreement with Janssen Pharmaceuticals to Develop and Commercialize AMYLOID β 42/40 RATIO Assay

The Lumipulse® series is intended to help identify patients who may benefit from treatment with Janssen’s new investigational oral BACE inhibitor, atabecestat.

April 26, 2018
·
2 min read